US Bancorp DE Buys 3,116 Shares of IQVIA Holdings Inc. $IQV

US Bancorp DE raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,509 shares of the medical research company's stock after acquiring an additional 3,116 shares during the quarter. US Bancorp DE's holdings in IQVIA were worth $4,808,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd grew its position in shares of IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock worth $28,000 after purchasing an additional 131 shares in the last quarter. Golden State Wealth Management LLC grew its position in shares of IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares in the last quarter. AllSquare Wealth Management LLC acquired a new position in shares of IQVIA during the 1st quarter worth approximately $33,000. Larson Financial Group LLC grew its position in shares of IQVIA by 109.9% during the 1st quarter. Larson Financial Group LLC now owns 275 shares of the medical research company's stock worth $48,000 after purchasing an additional 144 shares in the last quarter. Finally, Atticus Wealth Management LLC acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $52,000. 89.62% of the stock is owned by institutional investors.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on IQV. Evercore ISI increased their target price on shares of IQVIA from $220.00 to $240.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 8th. HSBC upgraded shares of IQVIA from a "hold" rating to a "buy" rating and increased their price target for the stock from $195.00 to $235.00 in a research report on Thursday. William Blair reiterated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. UBS Group increased their price target on shares of IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, Barclays increased their price target on shares of IQVIA from $185.00 to $200.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 2nd. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $234.57.

IQVIA Stock Performance

Shares of IQVIA stock opened at $203.95 on Tuesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.34. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $34.67 billion, a P/E ratio of 29.52, a P/E/G ratio of 2.18 and a beta of 1.32. The company's 50 day moving average price is $189.44 and its two-hundred day moving average price is $168.30.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter last year, the business posted $2.64 earnings per share. The company's quarterly revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.